Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Oct 15.

Published in final edited form as: Neuroscience. 2008 Aug 9;156(3):788–799. doi: 10.1016/j.neuroscience.2008.07.063

Fig. 7 — Regulation of hPC1/3 and hPC2 promoter activity by morphine. The human PC1/3-promoter-luciferase reporter construct, containing cDNA from −971 bp to −1 bp, relative to the translation initiation codon, and the PC1/3 construct containing cDNA from −971 bp to −1 bp with both CREs mutated were transiently transfected into GH3-μ receptor in 6-well plates (A). After six h, cells were incubated overnight in serum-free medium and subsequently treated with either 10 μM morphine, 10 μM naltrexone or 10 μM morphine plus 10 μM naltrexone for six h. Cells were then harvested and luciferase activity was measured. The results are expressed as mean ± SEM of luciferase activity compared to control cells of 3-4 experiments. Regulation of hPC2-promoter activity containing cDNA from −789 bp to −1 bp and hPC2-promoter containing cDNA from −789 bp to −1 bp promoter with its CREs mutated by morphine or morphine plus naltrexone in GH3-μ receptor cells (B). Regulation of hPC1/3 and hPC2 promoter activity by morphine in GH3 cells without expression of the mu-opioid receptor (C). *p<0.05, **p<0.0005.

Fig. 7 — Regulation of hPC1/3 and hPC2 promoter activity by morphine. The human PC1/3-promoter-luciferase reporter construct, containing cDNA from −971 bp to −1 bp, relative to the translation initiation codon, and the PC1/3 construct containing cDNA from −971 bp to −1 bp with both CREs mutated were transiently transfected into GH3-μ receptor in 6-well plates (A). After six h, cells were incubated overnight in serum-free medium and subsequently treated with either 10 μM morphine, 10 μM naltrexone or 10 μM morphine plus 10 μM naltrexone for six h. Cells were then harvested and luciferase activity was measured. The results are expressed as mean ± SEM of luciferase activity compared to control cells of 3-4 experiments. Regulation of hPC2-promoter activity containing cDNA from −789 bp to −1 bp and hPC2-promoter containing cDNA from −789 bp to −1 bp promoter with its CREs mutated by morphine or morphine plus naltrexone in GH3-μ receptor cells (B). Regulation of hPC1/3 and hPC2 promoter activity by morphine in GH3 cells without expression of the mu-opioid receptor (C). *p<0.05, **p<0.0005.